Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 14;12:745945. doi: 10.3389/fimmu.2021.745945

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wu, Jiang, Liu, Lu, Lv and Liang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Associations between molecular clusters and immune checkpoint blockade therapy. (A) Distribution of driver genes mutation, copy number alterations (CNAs) among the two molecular clusters. (B-D) Identification and validation of molecular clusters according to the CD8⁺ T cell-related genes in the Check-mate 025 cohort. (B) Kaplan-Meier analysis showed the Cluster1 patients had significantly poorer prognosis than Cluster2 patients. (C) Silhouette coefficients indicate that the sample is distinguished from neighboring clusters. (D) Differential expression tested the expression difference between two clusters. (E) The proportion of patients with response to Nivolumab immunotherapy in C1 and C2 cluster. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. (F) The proportion of patients with Deletions of 9p21.3 in C1 and C2 cluster. (G) The proportion of patients with PBRM1 mutations in C1 and C2 cluster.